Nan Fung Life Sciences
Jeni joined Nan Fung Life Sciences & Pivotal Life Sciences in 2019. Prior to Pivotal, she was at Novo Ventures supporting the firm’s investments across healthcare. Before joining Novo, Jeni supported the Director of Research at Aquilo Capital Management, a hedge fund focused on mid cap biotechs. Additionally, Jeni was a co-founder of ViVita Technologies, a cardiovascular-focused preclinical medtech startup. Jeni currently serves on the board of directors of Addition Therapeutics and DermBiont and as an observer for Secure Transfusion Services (STS). She previously served as an observer on the board of directors of Rallybio (NASDAQ:RLYB) and Inozyme Pharma (NASDAQ:INZY). Jeni volunteers with the Breaking 7% network to promote women in venture capital and previously volunteered with the New England Venture Network (NEVN). Jeni earned her Ph.D. in Biomedical Engineering with a Designated Emphasis in Biotechnology from the University of California, Davis, and her B.S. from the University of California, Berkeley.
This person is not in the org chart
This person is not in any offices
Nan Fung Life Sciences
Nan Fung Life Sciences, part of Nan Fung Group, is a global investment platform focusing on life sciences. Leveraging on Nan Fung Group’s strong capital base and long-term commitment to the area, the company is aimed to become the ideal partner for scientists, entrepreneurs, corporations, and investors in the life science space. Through direct investments via Pivotal bioVenture Partners funds (both in US and China) and fund investments covering full spectrum of the industry (including therapeutics, medical devices, and diagnostics) and across different development stages, Nan Fung Life Sciences has a significant presence in both US and Greater China.